FDA Clears Pharmaxis Cancer Drug to Progress to Phase 2 Study in Liver Cancer

9th Nov 21

Release Date: 09/11/2021 8:45am

  • IND approved to trial PXS-5505 added to current standard of care in newly diagnosed unresectable hepatocellular carcinoma patients
  • University of Rochester Medical Center and Pharmaxis in discussions to commence investigator-led study in 2022

Read full media release - pdf

Categories: News and Media